• Vk
  • LinkedIn
  • Youtube
X7 Research
  • News
  • Registration strategy and Сonsulting
    • Budgeting
    • Registration strategy development
    • Study feasibility
    • Vendor selection
    • Data search and analysis
  • Clinical trials
    • Outsourcing CRAs in Russia and the EAEU
    • Development of medical documentation and biostatistics
    • Monitoring
    • Data-management
    • Patient home visits
    • Bioequivalence study
    • Therapeutic equivalence studies
    • Clinical trials of medical devices
  • Registration
    • Audit of the registration dossier
    • Bringing the registration dossier in compliance with the requirements of the EAEU
    • Conversion of registration dossier into XML format
    • PIL readability user testing
    • Translation of the Registration dossier
    • Turnkey registration
  • Post-authorization clinical studies
    • Phase IV studies
    • Non-interventional studies
    • Investigator-initiated studies
    • Post-authorisation safety study
    • Marketing research
  • Pharmacovigilance
    • QPPV in the EAEU
    • Safety monitoring of medical devices
    • Building a pharmacovigilance system
    • Safety in clinical trials
    • Pharmacovigilance audit
    • Pharmacovigilance contact person
  • Therapeutic expertise
    • Clinical trials in Oncology in the EAEU
  • Contact
  • EnglishEnglish
    • РусскийРусский
  • Menu

NIS data: Approach to Data Acquisition System

02.06.2021/in Publications /by Marketing

Non-interventional studies (NIS), i.e., studies without interventions, where a medication is prescribed by a physician according to the routine practice of the specialist, have been growing in popularity every year since recent times. One of the characteristic features of conducting this kind of research is the wide variety of data sources; because of the focus on studying routine clinical practice, it is necessary to constantly remember that it did not create the data sources for their subsequent analysis in a clinical trial. The goals and approaches to the maintenance of these medical records are beyond the objectives of the research protocol. This specificity requires separate attention when preparing the information collection system. In this note, we will review some methods for ensuring the integrity of data collection within the NIS.

Data Sources

It represents actual practice data by the broadest set of sources, interpreting which in either may be useful for studying the use of medications. In English-language practice, the term Real-World Data (RWD) is widely used to describe the variety of such data. Conventionally, “real-world” data can be divided into two groups: public data and closed data. Examples of public data could be social media data, discovery datasets on adverse events, and de-identified open data on clinical trials. Closed sources are represented, for example, by medical records, electronic databases of laboratory tests, data from continuous condition monitoring devices, etc. As you can see, the sources differ not only in the type of information collected but also in the means of their carriage. Sometimes, it is possible to carry out an automatic transfer of data from one database to another, and sometimes manual input is required.

However, more important is the fact that the goals set in the research protocol operate with integral parameters, sums, averages, changes in dynamics, and so on. The analysis process requires a certain data structure specially prepared for data fixation and interpretation. In contrast to classical clinical research, where the structure of records can be determined by the protocol, NIS cannot interfere with the course of routine clinical practice. That is where preparing the data collection system becomes critical, as it is only at this stage that there is an opportunity to group disparate sources into a coherent database.

Controlling Study Endpoints

To ensure data integrity, it is first necessary to focus on the data collection process by an endpoint. This is required foremost to ensure that the data collection system has at its core a highly understandable set of records for all study participants. Using this approach, it is possible, first, to provide simple control of the filling of the data, on the key parameters, and second, having such a rigid structure, to add new input fields, linking them to the main parameters. To do this, the following questions need to be answered:

  • What are the characteristics of the endpoints?
  • What statistical methods of analysis will apply to this data?
  • How does the study design affect the collection of this data, is there retrospective data, is the data collection done vis-à-visor is the event a change in subject status?

Features of the eCRF design

Since a structured database needs to be organized to meet the objectives of the research protocol, the most convenient and logical way is to use Case Report Form (CRF), both electronic and paper, which would unify adapting real clinical practice records into a unified data collection system. Because of multiple sources, the local nature of medical record keeping, and the multicenter nature of studies, even the data entry process itself can gain a non-uniform nature, which can eventually lead to heterogeneity of the information got. This is especially true for paper-based CRFs since the absence of logical links between the forms, the absence of restrictions on entering data in the fields, and the longer and more complicated process of resolving requests for data clarification increase the risk of uncoordinated data collection. Thus, the most acceptable is the use of an electronic Data Acquisition System (DAS)  and, electronic CRF.

The wide variety of tools for data verification at the stage of input in the CRF in its turn should not lead to the situation of the impossibility of data input. When constructing the CRF form in NIS, it is necessary to remember:

  • The researcher still does the work of adapting your data.
  • It is impossible to foresee all variants of the collected values in advance.
  • There is a high probability of missing or partial data, which cannot be restored.

They must keep all these features in mind when designing the database structure,  ensure the collection of data on the one hand, and not create a situation of complete inability to enter data.

Share this entry
  • Share on Twitter
  • Share on WhatsApp
  • Share on Pinterest
  • Share on LinkedIn
  • Share on Tumblr
  • Share on Vk
  • Share on Reddit
  • Share by Mail

YOU MAY ALSO BE INTERESTED IN

Publications
Corrections to clinical trial documents due to COVID-19. Russian experience.
Read More
Publications
WHAT IS BIOEQUIVALENCE
Read More
Publications
THE VOLUME OF RUSSIAN PHARMACEUTICAL MARKET 2016-2019
Read More

RUBRICS

Registration strategy and Сonsulting

Clinical trials

Registration

Post-authorization clinical studies

Pharmacovigilance

LATEST PUBLICATIONS

  • Corrections to clinical trial documents due to COVID-19. Russian experience.
  • WHAT IS BIOEQUIVALENCE
  • THE VOLUME OF RUSSIAN PHARMACEUTICAL MARKET 2016-2019

Tags

bioequivalenceClinical trials in the CISfeasibilitymonitoringRadiopharmaceuticals

CONTACT

5 + 2 = ?

This contact form is deactivated because you refused to accept Google reCaptcha service which is necessary to validate any messages sent by the form.

PRIVACY

Use of this site constitutes your consent to our Privacy Policy.


SOCIAL RESPONSIBILITY

X7 Research’s primary responsibility is to help our clients in bringing medicines & products to the market efficiently and safely.

The Best CRO for Clinical Trials | Full-service Global CRO — X7 Research

The Best CRO in Pharma | Clinical Research Organisation — X7 Research

The Best Contract Research Organisation (CRO) | Trusted CRO — X7 Research

The Best Clinical Research Organisation (CRO): Full Service CRO | X7 Research

The Best CRO in Research | Trusted CRO for Your Trail — X7 Research

The Best Clinical Trial Company | Global Full-service CRO - X7 Research

The Best Pharma CROs: Clinical Trials for Drugs | X7 Research

The Best CROs Company: Clinical Trials with Global CRO — X7 Research

The Best Pre-clinical CRO: Safety Assessment With X7 Research

The Best Clinical Development | Trusted CRO for Your Product: X7 Research

The Best Biostatistical Consulting: Statistical Services | X7 Research

The Best Pharmacovigilance Consulting Services | CRO — X7 Research

Feasibility in Clinical Trials: What is a Feasibility in Clinical Trials?

Clinical Study Trials: What are Clinical Study Trials?

Category
Strategy and consulting
Clinical trials
Registration
Post-authorization clinical studies
Pharmacovigilance

Registration strategy and Сonsulting
Registration strategy development
Budgeting
Study feasibility
Vendor selection
Data search and analysis

Clinical trials
Development of medical documentation and biostatistics
Monitoring
Data management
Patient home visits
Bioequivalence study
Therapeutic equivalence studies

Registration
Audit of the registration dossier
Dossier eaeu
Conversion of registration dossier into xml format
Pil readability user testing
Turnkey registration

Post-authorization clinical studies
Phase iv studies
Non interventional studies
Investigator initiated studies
Post authorisation safety study
Marketing research

Pharmacovigilance
Building a pharmacovigilance system
Safety in clinical trials
Pharmacovigilance audit
Pharmacovigilance contact person

Blog
Contacts

© Copyright 2010-2023 - X7 Research. All rights reserved.
Early access programs for patients to non-registered drugs Current Practices of Non-Interventional Studies (NIS) in Russia
Scroll to top